Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension

Pediatric Cardiology

Volumn 31, Issue 5, 2010, Pages 598-606

  Barst, Robyn J ^a   Agnoletti, Gabriella ^b   Fraisse, Alain ^c   Baldassarre, James ^d   Wessel, David L ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c TIMONE HOSPITAL   (France)

^d MALLINCKRODT PHARMACEUTICALS   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

(MeSH headings) nitric oxide; Cardiovascular; Diagnostic techniques; Hypertension; Pulmonary

Indexed keywords

NITRIC OXIDE; OXYGEN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BRADYCARDIA; CARDIOMYOPATHY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ARREST; HEART CATHETERIZATION; HEART INDEX; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; HYPOXIA; INFANT; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; OPEN STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VASODILATATION; VITAL SIGN; ANALYSIS OF VARIANCE; CROSSOVER PROCEDURE; DIAGNOSTIC USE; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PULMONARY; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; VASCULAR RESISTANCE;

ADMINISTRATION, INHALATION; ADOLESCENT; ANALYSIS OF VARIANCE; CARDIAC CATHETERIZATION; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; MALE; NITRIC OXIDE; OXYGEN; PROSPECTIVE STUDIES; SURVIVAL RATE; VASCULAR RESISTANCE; VASODILATION;

EID: 77955102731     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-010-9645-5     Document Type: Article

References (25)

1. Atz AM, Adatia I, Lock JE, Wessel DL (1999) Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 33:813-819.
2. Badesch DB, Champion HC, Gomez-Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55-S66.
3. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD (2002) Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 106(12; Suppl 1):176-181.
4. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78-S84.
5. Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197-1208.
6. Barst RJ (1986) Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension. Chest 89:497-503.
7. Bennett D, Marcus R, Stokes M (2005) Incidents and complications during pediatric cardiac catheterization. Paediatr Anaesth 15:1083-1088.
8. Cockrill BA, Kacmarek RM, Fifer MA, Bigatello LM, Ginns LC, Zapol WM, Semigran MJ (2001) Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 119:128-136.
9. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Subirana Domenech MT, Vonk-Noordegraaf A, Zamorano JL (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493-2537.
10. Houde C, Bohn DJ, Freedom RM, Rabinovitch M (1993) Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 70:461-468.
11. Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelov B, Wennmalm A, Waagstein F, Lundin S (1994) Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13:366-375.
12. Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM (2000) Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 36:2204-2211.
13. Marshall HW, Swan HJ, Burchell HB, Wood EH (1961) Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. Circulation 23:241-252.
14. McLaughlin VM, Archer SA, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA (2009) ACCF/AHA clinical expert consensus document on pulmonary hypertension. Circulation 119:2250-2294.
15. Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, Rodriguez-Roisin R, Barbera JA (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98:225-234.
16. Pagano D, Townend JN, Horton R, Smith C, Clutton-Brock T, Bonser RS (1996) A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Eur J Cardiothorac Surg 10:1120-1126.
17. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173-1174.
18. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81.
19. Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM (1993) Inhaled nitric oxide in congenital heart disease. Circulation 87:447-453.
20. Rubin LJ (2004) Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(Suppl 1):7S-10S.
21. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151(2; Pt 1):384-389.
22. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265-270.
23. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105-3111.
24. Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR (2007) Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 98:657-661.
25. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660-665.